White arsenic local slow release chemical therapeutic medicine for treating malignant brain tumor

Abstract

The present invention discloses a slowly releasing system of white arsenic and biodegradable polymer as local chemotherapeutic medicine. It is implanted into the operation area after excising malignant tumor for post-operational treatment to prolonging the survival period of the malignant tumor patient. Through a compounding process, antitumor white arsenic is fused into biodegradable polymer in the amount of 3-6 times white arsenic weight. The biodegradable polymer may be PLA, PGA, PLGA and / or PFAD-SA. By means of corrosion and hydrolysis of the polymer, the medicine is released slowly, continuously and stably to act. The present invention is used in the local slowly releasing chemotherapy of malignant tumor in other system.

Description

Technical field: [0001] The invention belongs to a local slow-release drug, in particular to a local slow-release chemotherapeutic drug for treating malignant brain tumors. It belongs to the field of medical technology. technical background: [0002] Glioma accounts for the first place in central nervous system tumors and is one of the refractory diseases in neurosurgery. Due to the infiltrative growth of glioma and the unclear boundary with normal brain tissue, it is impossible to completely remove it by surgery, and recurrence often occurs after surgery. The average survival period of malignant glioma treated with surgery alone is only six months, while the average survival period of postoperative radiotherapy is no more than one year. In the past ten years, some progress has been made in chemotherapy, but it is difficult for chemotherapy drugs to pass through the blood-brain barrier through conventional intravenous administration. toxic side effect. [0003] Gliomas h...

AI Technical Summary

Problems solved by technology

However, most of them are administered by intravenous injection, and the intracranial distribution concentration is low